OnCo
trialsTrialCompleted

Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer

A phase 3 trial of Triptorelin in Prostate cancer, run by Ipsen, completed.